HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ERC-07-0240v1 15/4/985    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Pancholi, S. Articles by Martin, L.-A. Search for Related Content PubMed PubMed Citation Articles by Pancholi, S. Articles by Martin, L.-A.

Institute of Cancer Research, The Breakthrough Breast Cancer Research Centre, 237 Fulham Road, London SW3 6JB, UK¹ Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark² Department of Medicine, Royal Marsden Hospital, Fulham Road, London, UK

(Correspondence should be addressed to L-A Martin; Email: lesley-ann.martin{at}icr.ac.uk)

Acquired resistance to endocrine therapies remains a major clinical obstacle in hormone-sensitive breast tumors. We used an MCF-7 breast tumor cell line (Tam^R-1) resistant to tamoxifen to investigate this mechanism. We demonstrate that Tam^R-1 express elevated levels of phosphorylated AKT and MAPK3/1-activated RPS6KA2 compared with the parental MCF-7 cell line (MCF-7). There was no change in the level of total ESR between the two cell lines; however, the Tam^R-1 cells had increased phosphorylation of ESR1 ser¹⁶⁷. SiRNA blockade of AKT or MAPK3/1 had little effect on ESR1 ser¹⁶⁷ phosphorylation, but a combination of the two siRNAs abrogated this. Co-localization studies revealed an association between ERBB2 and ESR1 in the Tam^R-1 but not MCF-7 cells. ESR1 was redistributed to extranuclear sites in Tam^R-1 and was less transcriptionally competent compared with MCF-7 suggesting that nuclear ESR1 activity was suppressed in Tam^R-1. Tamoxifen resistance in the Tam^R-1 cells could be partially overcome by the ERBB2 inhibitor AG825 in combination with tamoxifen, and this was associated with re-localization of ESR1 to the nucleus. These data demonstrate that tamoxifen-resistant cells have the ability to switch between ERBB2 or ESR1 pathways promoting cell growth and that pharmacological inhibition of ERBB2 may be a therapeutic strategy for overcoming tamoxifen resistance.

This article has been cited by other articles:

				S. R.D. Johnston Role of the mTOR Pathway in Endocrine-resistant Breast Cancer -- Opportunities for Novel Combination Strategies ASCO Educational Book, January 1, 2009; 2009(1): 20 - 28. [Abstract] [Full Text] [PDF]